Kapag ang pangunahing kanser sa atay ay nauugnay sa ascites, jaundice, malayong metastasis, atbp., ito ay tinatawag na advanced na pangunahing kanser sa atay. Ang paggamot ng advanced na pangunahing kanser sa atay ay mahirap, at ang klinikal na epekto ng paggamot ay hindi perpekto. Ang operasyon ay hindi isang opsyon para sa paggamot sa advanced na kanser sa atay dahil ito ay kumalat sa mga lymph node o iba pang mga organo.
If the liver is in good condition (Child-Pugh grade A or B), the doctor will consider treatment with the targeted therapeutic drugs Sorafenib (Nexavar) or Lenvama (Lenvima). Growth can prolong the survival time of patients. If the patient develops drug resistance, the targeted drug repaglinide (Stivarga) or the immunotherapy drug nivolumab (Opdivo) can be used instead.
In addition, keeping an eye on clinical trial information at any time and actively participating in relevant clinical trials such as chemotherapy, radiotherapy, and immunotherapy may also bring opportunities and hope for patients with advanced kanser sa atay. It is hoped that in the next few years, researchers will make a huge breakthrough in the field of liver cancer diagnosis and treatment.
